巴瑞替尼治疗重度斑秃:48周真实世界研究
这项意大利27家大学医院的48周回顾性观察研究纳入253例重度斑秃成人患者,评估巴瑞替尼4 mg/日治疗的真实疗效与安全性。第48周63.2%患者达到SALT≤20,平均SALT评分从93.7降至26.5(p<0.001),生活质量与情绪评分显著改善,9.4%报告不良事件。
要点
- 巴瑞替尼4 mg/日治疗48周,63.2%重度斑秃患者达到SALT≤20。
- 平均SALT评分从基线93.7显著降至第48周26.5(p<0.001)。
- 9.4%患者报告不良事件,真实世界中疗效与安全性获验证。
核心结论
- 真实世界研究证实巴瑞替尼4 mg/日治疗48周可显著促进重度斑秃患者毛发再生并改善心理状态。
研究设计与样本
- 48周回顾性、观察性、多中心研究,覆盖意大利27家大学医院。
主要发现
- 第48周63.2%患者达到SALT≤20,75.5%达到SALT≤30。
- 平均SALT评分从基线93.7±14.1显著降至第48周26.5±33.0(p<0.001)。
- 皮肤镜检查显示黄点(97.6%降至50.2%)、黑点(43.5%降至9.1%)、营养不良发(14.6%降至4.3%)减少,再生毛发(7.1%升至80.2%)增加。
- Skindex-16评分从57.1±25.0改善至30.0±17.8(p<0.001),HADS焦虑评分从8.21±9.38降至4.62±4.21(p<0.001),HADS抑郁评分从6.36±4.55降至3.70±4.11(p<0.001)。
- 9.4%患者报告不良事件。
关键数值与推荐
- 疗效主要指标为第48周达到SALT≤20的患者比例。
- 次要指标包括平均SALT评分变化、皮肤镜表现、Skindex-16、HADS及眉毛/睫毛ClinRO。
临床怎么用
- 巴瑞替尼4 mg/日可作为重度斑秃成人患者的真实世界治疗选择,需定期随访监测疗效与不良反应。
局限性
- 回顾性观察性设计,无对照组。
- 仅纳入意大利成人患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alopecia areata (AA) is an autoimmune condition leading to hair loss. Baricitinib, a Janus kinase (JAK) inhibitor, has demonstrated efficacy in controlled clinical trials, but real-world data on its long-term effectiveness and safety remain limited. OBJECTIVES: This study aimed to assess the real-life effectiveness and safety of baricitinib 4 mg daily in Italian adult patients with severe AA over a 48-week treatment period. METHODS: We conducted a 48-week retrospective, observational, multicenter study across 27 Italian university hospitals. Adult patients (18-65 years) with severe AA (Severity of Alopecia Tool [SALT] score ≥ 50) who initiated baricitinib 4 mg daily treatment between November 2022 and October 2023 were included. Effectiveness was measured by the percentage of patients achieving SALT ≤20 at week 48. Secondary outcomes included changes in mean SALT score, trichoscopic findings, patient-reported quality of life (Skindex-16, Hospital Anxiety and Depression Scale [HADS]), and Clinician-Reported Outcomes (ClinRO) for eyebrows and eyelashes. Adverse events were also documented. RESULTS: A total of 253 patients (66.8% females, mean age 40.0 ± 12.6 years) were included. By week 48, 63.2% achieved SALT ≤20, and 75.5% achieved SALT ≤30. The mean SALT score significantly decreased from 93.7 ± 14.1 at baseline to 26.5 ± 33.0 at week 48 (p < 0.001). Trichoscopic assessment showed a decline in yellow dots (97.6%-50.2%), black dots (43.5%-9.1%), and dystrophic hairs (14.6%-4.3%), whilst regrowing hairs increased (7.1%-80.2%). Skindex-16 scores improved significantly (57.1 ± 25.0 to 30.0 ± 17.8, p < 0.001), as did HADS Anxiety (8.21 ± 9.38 to 4.62 ± 4.21, p < 0.001) and HADS Depression (6.36 ± 4.55 to 3.70 ± 4.11, p < 0.001). Adverse events were reported in 9.4% of patients. CONCLUSIONS: This real-world study confirms the effectiveness of baricitinib in achieving significant hair regrowth and improving psychological well-being in severe AA patients. UNLABELLED: WHAT IS THE DISEASE?: Alopecia areata (AA) is an autoimmune condition that causes sudden hair loss on the scalp, face, or body. Severe forms can result in complete loss of scalp hair (alopecia totalis) or all body hair (alopecia universalis). It affects both men and women and can significantly impact emotional well‐being. LOCATION OF THE STUDY: This study was conducted in Italy, involving 27 university hospitals. AIM OF THE STUDY: We wanted to understand how well baricitinib, a medicine that blocks specific immune signals (JAK1/2), works and how safe it is for adults with severe AA in everyday clinical practice over 48 weeks. METHODOLOGY: We reviewed the medical records of 253 adults (aged 18–65 years) with severe AA who started baricitinib 4 mg daily between November 2022 and October 2023. We measured hair regrowth using the Severity of Alopecia Tool (SALT) and assessed eyebrow/eyelash changes, scalp examination with a dermatoscope (trichoscopy), quality of life, mood, and treatment safety. KEY FINDINGS: After 48 weeks, 63% of patients had major scalp hair regrowth (SALT ≤20), and over 75% had moderate regrowth (SALT ≤30). Trichoscopy showed more regrowing hairs and fewer disease signs. Quality‐of‐life scores improved, and symptoms of anxiety and depression decreased. Side effects occurred in about 9% of patients, mostly mild. CONCLUSIONS AND PRACTICAL IMPLICATIONS: In real‐world settings, baricitinib can restore hair and improve mental health in many people with severe AA. Regular follow‐up is important to monitor progress and detect side effects.
引用
- Piraccini BM, Cedirian S, Pampaloni F, et al. Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results. J Eur Acad Dermatol Venereol. 2025. PMID: 40985491. doi:10.1111/jdv.70067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。